{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kumar P"],"funding":["Bill & Melinda Gates Foundation","Bill &amp;amp; Melinda Gates Foundation"],"pagination":["609"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11209613"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(6)"],"pubmed_abstract":["Introducing new recombinant protein antigens to existing pediatric combination vaccines is important in improving coverage and affordability, especially in low- and middle-income countries (LMICs). This case-study highlights the analytical and formulation challenges encountered with three recombinant non-replicating rotavirus vaccine (NRRV) antigens (t-NRRV formulated with Alhydrogel<sup>®</sup> adjuvant, AH) combined with a mock multidose formulation of a pediatric pentavalent vaccine used in LMICs. This complex formulation contained (1) vaccine antigens (i.e., whole-cell pertussis (wP), diphtheria (D), tetanus (T), <i>Haemophilus influenza</i> (Hib), and hepatitis B (HepB), (2) a mixture of aluminum-salt adjuvants (AH and Adju-Phos<sup>®</sup>, AP), and (3) a preservative (thimerosal, TH"],"journal":["Vaccines"],"pubmed_title":["Evaluating the Compatibility of New Recombinant Protein Antigens (Trivalent NRRV) with a Mock Pentavalent Combination Vaccine Containing Whole-Cell Pertussis: Analytical and Formulation Challenges."],"pmcid":["PMC11209613"],"funding_grant_id":["INV-009301","OPP1212920"],"pubmed_authors":["Saleh-Birdjandi S","Volkin DB","Secrist K","Joshi SB","Dotson B","Adewunmi Y","Taskar P","Holland DA","Mantis NJ","Kumar P","Doering J"],"additional_accession":[]},"is_claimable":false,"name":"Evaluating the Compatibility of New Recombinant Protein Antigens (Trivalent NRRV) with a Mock Pentavalent Combination Vaccine Containing Whole-Cell Pertussis: Analytical and Formulation Challenges.","description":"Introducing new recombinant protein antigens to existing pediatric combination vaccines is important in improving coverage and affordability, especially in low- and middle-income countries (LMICs). This case-study highlights the analytical and formulation challenges encountered with three recombinant non-replicating rotavirus vaccine (NRRV) antigens (t-NRRV formulated with Alhydrogel<sup>®</sup> adjuvant, AH) combined with a mock multidose formulation of a pediatric pentavalent vaccine used in LMICs. This complex formulation contained (1) vaccine antigens (i.e., whole-cell pertussis (wP), diphtheria (D), tetanus (T), <i>Haemophilus influenza</i> (Hib), and hepatitis B (HepB), (2) a mixture of aluminum-salt adjuvants (AH and Adju-Phos<sup>®</sup>, AP), and (3) a preservative (thimerosal, TH","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-05-05T03:21:19.304Z","creation":"2025-04-04T21:22:41.512Z"},"accession":"S-EPMC11209613","cross_references":{"pubmed":["38932338"],"doi":["10.3390/vaccines12060609"]}}